Posted by Michael Wonder on 08 Dec 2022
Osteoporosis after menopause: fewer vertebral fractures with teriparatide than with risedronate
5 December 2022 - The final report of the IQWiG on the comparative benefit assessment of bisphosphonates, teriparatide and denosumab is now available - there is no change in the results compared to the previous report.
Medicines used to treat women with post-menopausal osteoporosis usually include those that prevent bone loss (these include bisphosphonates such as risedronate and monoclonal antibodies such as denosumab) or medicines that stimulate bone formation (this includes teriparatide).
